Cited by 764Colorectal Cancer Surgical TreatmentsColorectal and Anal CarcinomasGastric Cancer Management and Outcomes

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

Open access

Aschele, Carlo, Cionini, Luca, Lonardi, Sara, Pinto, Carmine, Cordio, Stefano, Rosati, Gerardo, Artale, Salvatore, Tagliagambe, Angiolo, Ambrosini, Giovanni, Rosetti, Paola, Bonetti, Andrea, Negru, Maria Emanuela, Tronconi, Maria Chiara, Luppi, Gabriele, Silvano, Giovanni, Corsi, Domenico Cristiano, Bochicchio, Anna Maria, Chiaulon, Germana, Gallo, Maurizio, Boni, Luca·2011·Journal of Clinical Oncology

DOI 10.1200/jco.2010.34.4911

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: To investigate oxaliplatin combined with fluorouracil-based chemoradiotherapy as preoperative treatment for locally advanced rectal cancer. Patients and Methods: Seven hundred forty-seven patients with resectable, locally advanced (cT3-4 and/or cN1-2) adenocarcinoma of the mid-low rectum were randomly assigned to receive pelvic radiation (50.4 Gy in 28 daily fractions) and concomitant infused fluorouracil (225 mg/m 2 /d) either alone (arm A, n = 379) or combined with oxaliplatin (60 mg/m 2 weekly × 6; arm B, n = 368). Overall survival is the primary end point. A protocol-planned analysis of response to preoperative treatment is reported here. Results: Grade 3 to 4 adverse events during preoperative treatment were more frequent with oxaliplatin plus fluorouracil and radiation than with radiation and fluorouracil alone (24% v 8% of treated patients; P < .001). In arm B, 83% of the patients treated with oxaliplatin had five or more weekly administrations. Ninety-one percent, compared with 97% in the control arm, received ≥ 45 Gy (P < .001). Ninety-six percent versus 95% of patients underwent surgery with similar rates of abdominoperineal resections (20% v 18%, arm A v arm B). The rate of pathologic complete responses was 16% in both arms (odds ratio = 0.98; 95% CI, 0.66 to 1.44; P = .904). Twenty-six percent versus 29% of patients had pathologically positive lymph nodes (arm A v arm B; P = .447), 46% versus 44% had tumor infiltration beyond the muscularis propria (P = .701), and 7% versus 4% had positive circumferential resection margins (P = .239). Intra-abdominal metastases were found at surgery in 2.9% versus 0.5% of patients (arm A v arm B; P = .014). Conclusion: Adding oxaliplatin to fluorouracil-based preoperative chemoradiotherapy significantly increases toxicity without affecting primary tumor response. Longer follow-up is needed to assess the impact on efficacy end points.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2010.34.4911

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040694 · Cited by 6,050
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citation
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Zaninelli, M., Clingan, P. R., Bridgewater, J. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,694
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., & Ollier, J.-C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060829 · Cited by 2,688
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
Gérard, J.-P., Conroy, T., Bonnetain, F., Bouché, O., Chapet, O., Closon-Dejardin, M.-T., Untereiner, M., Leduc, B., Francois, É., Maurel, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7629 · Cited by 1,731
Pathological features of rectal cancer after preoperative radiochemotherapy
Dworak, O., Keilholz, L., & Hoffmann, A. (1997) · International Journal of Colorectal Disease · doi:10.1007/s003840050072 · Cited by 1,344
Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy
Trotti, A., Byhardt, R. W., Stetz, J., Gwede, C. K., Corn, B. W., Fu, K. K., Gunderson, L. L., McCormick, B. L., Morris∫, M., Rich, T. A., et al. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00559-3 · Cited by 805
Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2
Gérard, J.-P., Azria, D., Gourgou-Bourgade, S., Martel-Laffay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, E., de La Roche, G., Bouché, O., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8376 · Cited by 747
Enhanced Tumorocidal Effect of Chemotherapy With Preoperative Radiotherapy for Rectal Cancer: Preliminary Results—EORTC 22921
Bosset, J.-F., Calais, G., Mineur, L., Maingon, P., Radošević-Jelić, L., Daban, A., Bardet, É., Beny, A., Briffaux, A., & Collette, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.113 · Cited by 594
Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer
Chau, I., Brown, G. M., Cunningham, D., Tait, D., Wotherspoon, A. C., Norman, A. R., Tebbutt, N. C., Hill, M. E., Ross, P. J., Massey, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4875 · Cited by 472

Show all 29 references

Research works printed but not linked: 1

LH Sobin, CH Wittekind : International Union Against Cancer (UICC) TNM classification of malignant tumours 1997 5th ed New York, NY John Wiley & Sons

Sorted by citations

Colorectal cancer
Brenner, H., Kloor, M., & Pox, C. P. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61649-9 · Cited by 3,057
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glynne‐Jones, R., Wyrwicz, L. S., Tiret, E., Brown, G. M., Rödel, C. M., Cervantes, A. M. R., & Arnold, D. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx224 · Cited by 2,098
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
Hashiguchi, Y., Muro, K., Saitō, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,950
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glimelius, B. L. G., Tiret, E., Cervantes, A. M. R., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt240 · Cited by 1,792
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
Schmoll, H., Cutsem, E. V., Stein, A., Valentini, V., Glimelius, B. L. G., Haustermans, K. M., Nordlinger, B., van de Velde, C. J., Balmañà, J., Reguła, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,534
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Engstrom, P. F., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0061 · Cited by 947
Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04
Ngan, S. Y., Burmeister, B. H., Fisher, R., Solomon, M. J., Goldstein, D., Joseph, D. J., Ackland, S. P., Schache, D. J., McClure, B., McLachlan, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.9597 · Cited by 917
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Azad, N. A., Chen, Y., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Garrido‐Laguna, I., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0051 · Cited by 866
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
Rödel, C. M., Graeven, U., Fietkau, R., Hohenberger, W., Hothorn, T., Arnold, D., Hofheinz, R., Ghadimi, M. B., Wolff, H. A., Lang-Welzenbach, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00159-x · Cited by 736
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial
García‐Aguilar, J., Chow, O. S., Smith, D. D., Marcet, J. E., Cataldo, P. A., Varma, M. G., Kumar, A. S., Oommen, S. C., Coutsoftides, T., Hunt, S. R., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00004-2 · Cited by 699
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial
Rödel, C., Liersch, T., Becker, H., Fietkau, R., Hohenberger, W., Hothorn, T., Graeven, U., Arnold, D., Lang-Welzenbach, M., Raab, H.-R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70187-0 · Cited by 696
Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Cercek, A., Roxburgh, C. S. D., Strombom, P. D., Smith, J. J., Temple, L. K. F., Nash, G. M., Guillem, J. G., Paty, P. B., Yaeger, R. D., Stadler, Z. K., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0071 · Cited by 653
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
Watanabe, T., Itabashi, M., Shimada, Y., Tanaka, S., Ito, Y., Ajioka, Y., Hamaguchi, T., Hyodo, I., Igarashi, M., Ishida, H., et al. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0801-z · Cited by 596
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
Hofheinz, R.-D., Wenz, F., Post, S., Matzdorff, A., Laechelt, S., Hartmann, J. T., Müller, L., Link, H., Moehler, M., Kettner, E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70116-x · Cited by 509
Past, present, and future of radiotherapy for the benefit of patients
Thariat, J., Hannoun‐Lévi, J., Myint, A. S., Vuong, T., & Gérard, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.203 · Cited by 476
Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial
García‐Aguilar, J., Renfro, L. A., Chow, O. S., Shi, Q., Carrero, X. W., Lynn, P. B., Thomas, C. R., Chan, E. W., Cataldo, P. A., Marcet, J. E., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00215-6 · Cited by 448
Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study
Bujko, K., Wyrwicz, L. S., Rutkowski, A., Malinowska, M., Pietrzak, L., Kryński, J., Michalski, W., Olędzki, J., Kuśnierz, J., Zając, L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw062 · Cited by 442
Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04
O’Connell, M. J., Colangelo, L. H., Beart, R. W., Petrelli, N. J., Allegra, C. J., Sharif, S., Pitot, H. C., Shields, A. F., Landry, J. C., Ryan, D. P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7753 · Cited by 439
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer
Gérard, J.-P., Azria, D., Gourgou-Bourgade, S., Martel-Lafay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, E., de La Roche, G., Bouché, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8771 · Cited by 430
EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum
van de Velde, C. J. �., Boelens, P. G., Borràs, J. M., Coebergh, J. W. W., Cervantes, A. M. R., Blomqvist, L., Beets‐Tan, R. G. H., van den Broek, C. B. M., Brown, G. M., Cutsem, E. V., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.048 · Cited by 404
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial
Deng, Y., Chi, P., Lan, P., Wang, L., Chen, W., Cui, L., Daoda, C., Cao, J., Wei, H., Peng, X., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6198 · Cited by 398
Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)
Dewdney, A., Cunningham, D., Tabernero, J. M., Capdevila, J., Glimelius, B. L. G., Cervantes, A. M. R., Tait, D., Brown, G. M., Wotherspoon, A. C., de Castro, D. G., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6036 · Cited by 388
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial
Hong, Y. S., Nam, B., Kim, K., Kim, J. E., Park, S., Park, Y. S., Park, J. O., Kim, S. Y., Im, S., Kim, J. H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70377-8 · Cited by 384
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
Deng, Y., Chi, P., Lan, P., Wang, L., Chen, W., Cui, L., Daoda, C., Cao, J., Wei, H., Peng, X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02309 · Cited by 378
The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer
You, Y. N., Hardiman, K. M., Bafford, A. C., Poylin, V. Y., Francone, T. D., Davis, K. G., Paquette, I. M., Steele, S. R., & Feingold, D. L. (2020) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001762 · Cited by 369
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial
Allegra, C. J., Yothers, G., O’Connell, M. J., Beart, R. W., Wozniak, T. F., Pitot, H. C., Shields, A. F., Landry, J. C., Ryan, D. P., Arora, A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv248 · Cited by 325
Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study
Ciseł, B., Pietrzak, L., Michalski, W., Wyrwicz, L. S., Rutkowski, A., Kosakowska, E., Cencelewicz-Lesikow, A., Spalek, M. J., Polkowski, W. P., Jankiewicz, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz186 · Cited by 324
Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline
Chino, J., Annunziata, C. M., Beriwal, S., Bradfield, L., Erickson, B. A., Fields, E. C., Fitch, K., Harkenrider, M. M., Holschneider, C. H., Kamrava, M. R., et al. (2020) · Practical Radiation Oncology · doi:10.1016/j.prro.2020.04.002 · Cited by 320
Radiation Dose-Response Model for Locally Advanced Rectal Cancer After Preoperative Chemoradiation Therapy
Appelt, A. L., Pløen, J., Vogelius, I. R., Bentzen, S. M., & Jakobsen, A. K. M. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.05.017 · Cited by 292
Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer
Sloothaak, D., Geijsen, D. E., van Leersum, N. J., Punt, C. J. A., Buskens, C. J., Bemelman, W. A., & Tanis, P. J. (2013) · British journal of surgery · doi:10.1002/bjs.9112 · Cited by 288
No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT)
Sainato, A., Nunzia, V. C. L., Valentini, V., Paoli, A. D., Maurizi, E. R., Lupattelli, M., Aristei, C., Vidali, C., Conti, M., Galardi, A., et al. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.10.006 · Cited by 293
Self-citation
A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
Li, Y., Ji, W., Ma, X., Tan, L., Yan, Y., Xue, C., Hui, B., Liu, R., Ma, H., & Ren, J. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15438 · Cited by 282
Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma
Chatterjee, D., Katz, M. H. G., Rashid, A., Varadhachary, G. R., Wolff, R. A., Wang, H., Lee, J. E., Pisters, P. W. T., Vauthey, J., Crane, C. H., et al. (2011) · Cancer · doi:10.1002/cncr.26651 · Cited by 260
Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes
Collaborative, T. B. T., Ali, S. M., Antoniou, A., Beynon, J. L., Bhangu, A. A., Bose, P., Boyle, K., Branagan, G., Brown, G. M., Burling, D. N., et al. (2013) · British journal of surgery · doi:10.1002/bjs.9192_1 · Cited by 259
S3-Leitlinie – Kolorektales Karzinom
Schmiegel, W., Buchberger, B., Follmann, M., Graeven, U., Heinemann, V., Langer, T. G., Nothacker, M., Porschen, R., Rödel, C. M., Rösch, T., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-121106 · Cited by 247
Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial
van der Valk, M. J. M., Marijnen, C. A. M., van Etten, B., Dijkstra, E. A., Hilling, D. E., Kranenbarg, E. M., Putter, H., Roodvoets, A. G. H., Bahadoer, R. R., Fokstuen, T., et al. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.03.011 · Cited by 220
Advances and Challenges in Treatment of Locally Advanced Rectal Cancer
Smith, J. J., & García‐Aguilar, J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1054 · Cited by 216
Early colorectal cancer: diagnosis, treatment and survivorship care
Buccafusca, G., Proserpio, I., Tralongo, A. C., Giuliano, S. R., & Tralongo, P. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.01.023 · Cited by 216
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial
Qin, Q., Ma, T., Deng, Y., Zheng, J., Zhou, Z., Wang, H., Wang, L., & Wang, J. (2016) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000665 · Cited by 167
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial
Hong, Y. S., Kim, S. Y., Lee, J. S., Nam, B., Kim, K., Kim, J. E., Park, Y. S., Park, J. O., Baek, J. Y., Kim, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00016 · Cited by 165
Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer
Montroni, I., Ugolini, G., Saur, N. M., Spinelli, A., Rostoft, S., Millán, M., Wolthuis, A. M., Daniels, I. R., Hompes, R., Penna, M., et al. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.08.003 · Cited by 145
Rectal Cancer
Benson, A. B., Bekaii‐Saab, T., Chan, E. W., Chen, Y., Choti, M. A., Cooper, H. S., Engstrom, P. F., Enzinger, P. C., Fakih, M., Fuchs, C. S., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0158 · Cited by 145
Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline
Wo, J. Y.-L., Anker, C. J., Ashman, J. B., Bhadkamkar, N. A., Bradfield, L., Chang, D. T., Dorth, J. A., García‐Aguilar, J., Goff, D. C., Jacqmin, D. J., et al. (2020) · Practical Radiation Oncology · doi:10.1016/j.prro.2020.08.004 · Cited by 145
Management of colorectal cancer
Stintzing, S. (2014) · F1000Prime Reports · doi:10.12703/p6-108 · Cited by 152
Association of Coloproctology of Great Britain & Ireland ( ACPGBI ): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) – Multidisciplinary Management
Gollins, S., Moran, B. J., Adams, R., Cunningham, C., Bach, S. P., Myint, A. S., Renehan, A. G., Karandikar, S. S., Goh, V., Prezzi, D., et al. (2017) · Colorectal Disease · doi:10.1111/codi.13705 · Cited by 138
Neoadjuvant Oxaliplatin and Capecitabine and Bevacizumab without Radiotherapy for Poor-risk Rectal Cancer: N-SOG 03 Phase II Trial
Uehara, K., Hiramatsu, K., Maeda, A., Sakamoto, E., Inoue, M., Kobayashi, S., Tojima, Y., Yoshioka, Y., Nakayama, G., Yatsuya, H., et al. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt115 · Cited by 137
Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer
Zhu, J. Y., Liu, A., Sun, X., Liu, L., Zhu, Y., Zhang, T., Jia, J., Tan, S., Wu, J., Wang, X., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01932 · Cited by 129
Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis
Zhao, Q., Rashid, A., Gong, Y., Katz, M. H. G., Lee, J. E., Wolf, R., Balachandran, A., Varadhachary, G. R., Pisters, P. W. T., Wang, H., et al. (2011) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2011.08.005 · Cited by 130
Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)
Gérard, J., André, T., Bibeau, F., Conroy, T., Legoux, J.-L., Portier, G., Bosset, J.-F., Cadiot, G., Bouché, O., & Bedenne, L. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.01.152 · Cited by 128
Neoadjuvant Radiotherapy for Rectal Cancer: Meta-analysis of Randomized Controlled Trials
Rahbari, N. N., Elbers, H., Askoxylakis, V., Motschall, E., Bork, U., Büchler, M. W., Weitz, J., & Koch, M. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3198-9 · Cited by 128
Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review
Péron, J., Maillet, D., Gan, H. K., Chen, E. X., & You, B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3981 · Cited by 132
Current status and future perspectives on treatment of liver metastasis in colorectal cancer
Bandar, M. H. A., & Kim, N. K. (2017) · Oncology Reports · doi:10.3892/or.2017.5531 · Cited by 126
NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer
Hong, T. S., Moughan, J., Garofalo, M. C., Bendell, J. C., Berger, A. C., Oldenburg, N. B. E., Anne, P. R., Perera, F. E., Lee, R. J., Jabbour, S. K., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.05.005 · Cited by 120
Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study
Araújo, R. O., Valadão, M., Borges, D., Linhares, E., de Jesus, J. P., Ferreira, C. G., Victorino, A. P., Vieira, F. M. D. A. C., & Albagli, R. D. O. (2015) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2015.08.156 · Cited by 112
Locally advanced rectal cancer: The past, present, and future
Oronsky, B. T., Reid, T. R., Larson, C., & Knox, S. J. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.02.001 · Cited by 106
Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management
Franke, A. J., Parekh, H. D., Starr, J. S., Tan, S., Iqbal, A., & George, T. J. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.06.008 · Cited by 105
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer
Azria, D., Doyen, J., Jarlier, M., Martel‐Lafay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, É., Roche, G., Bouché, O., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx351 · Cited by 101
Advances in the management of colorectal cancer: from biology to treatment
Ahmed, S., JOHNSON, K., Ahmed, O., & Iqbal, N. (2014) · International Journal of Colorectal Disease · doi:10.1007/s00384-014-1928-5 · Cited by 106
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?
Bonnetain, F., Bosset, J. F., Gérard, J., Calais, G., Conroy, T., Mineur, L., Bouché, O., Maingon, P., Chapet, O., Radošević-Jelić, L., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.016 · Cited by 106
Outcome measures in multimodal rectal cancer trials
Fokas, E., Glynne‐Jones, R., Appelt, A. L., Beets‐Tan, R. G. H., Beets, G. L., Haustermans, K. M., Marijnen, C. A. M., Minsky, B. D., Ludmir, E. B., Quirke, P., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30024-3 · Cited by 101
Neither FDG-PET Nor CT Can Distinguish Between a Pathological Complete Response and an Incomplete Response After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
Guillem, J. G., Ruby, J. A., Leibold, T., Akhurst, T., YEUNG, H. W. D., Gollub, M. J., Ginsberg, M. S., Shia, J., Suriawinata, A. A., Riedel, E., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e318277b625 · Cited by 101
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD
Schmoll, H., Stein, A., Cutsem, E. V., Price, T. J., Hofheinz, R., Nordlinger, B., Daisne, J., Janssens, J., Brenner, B., Reinel, H. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01740 · Cited by 99
Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced rectal cancer
Ryan, É. J., O'Sullivan, D. P., Kelly, M. E., Syed, A. Z., Neary, P. C., O’Connell, P. R., Kavanagh, D. O., Winter, D. C., & O’Riordan, J. M. (2019) · British journal of surgery · doi:10.1002/bjs.11220 · Cited by 100
The current landscape of locally advanced rectal cancer
Aklilu, M., & Eng, C. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.118 · Cited by 95
Making sense of adjuvant chemotherapy in colorectal cancer
Chan, G. H. J., & Chee, C. E. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.06.03 · Cited by 82
Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives
Häfner, M. F., & Debus, J. (2016) · Visceral Medicine · doi:10.1159/000446486 · Cited by 104
Oxaliplatin: a review of approved uses
Stein, A., & Arnold, D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.643870 · Cited by 91
Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial
Mei, W.-J., Wang, X., Li, Y., Sun, Y., Yang, C., Lin, J., Wu, Z., Zhang, R., Wang, W., Li, Y., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005780 · Cited by 92
Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study
Velenik, V., Ocvirk, J., Mušič, M. M., Bračko, M., Anderluh, F., Oblak, I., Edhemović, I., Brecelj, E., Kropivnik, M., & Omejc, M. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-105 · Cited by 88
CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α
Tian, X., Nguyen, M., Foote, H. P., Caster, J. M., Roche, K. C., Peters, C. G., Wu, P., Jayaraman, L., Garmey, E. G., Tepper, J. E., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2951 · Cited by 91
Neoadjuvant Treatment Strategies for Locally Advanced Rectal Cancer
Gollins, S., & Sebag‐Montefiore, D. (2015) · Clinical Oncology · doi:10.1016/j.clon.2015.11.003 · Cited by 91
Treatment of Locally Advanced Rectal Cancer in the Era of Total Neoadjuvant Therapy
Turri, G., Ostuzzi, G., Vita, G., Barresi, V., Scarpa, A., Milella, M. S., Mazzarotto, R., Ruzzenente, A., Barbui, C., & Pedrazzani, C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.14702 · Cited by 88
Organ preservation in rectal cancer: have all questions been answered?
Marijnen, C. A. M. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70398-5 · Cited by 89
Future direction of total neoadjuvant therapy for locally advanced rectal cancer
Kagawa, Y., Smith, J. J., Fokas, E., Watanabe, J., Cercek, A., Greten, F. R., Bando, H., Shi, Q., García‐Aguilar, J., Romesser, P. B., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00900-9 · Cited by 88
Systematic review of outcomes after total neoadjuvant therapy for locally advanced rectal cancer
Zaborowski, A. M., Stakelum, Á., & Winter, D. C. (2019) · British journal of surgery · doi:10.1002/bjs.11171 · Cited by 80
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer
Kinugasa, Y., Uehara, K., Yamaguchi, K., Saito, Y., Murofushi, K. N., Sugai, T., Ishiguro, M., Ishihara, S., Ueno, H., Oka, S., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02899-8 · Cited by 99
Complete Neoadjuvant Treatment for Rectal Cancer
Perez, K. J., Safran, H., Sikov, W. M., Vrees, M. D., Klipfel, A. A., Shah, N. J., Schechter, S., Oldenburg, N. B. E., Pricolo, V. E., Rosati, K., et al. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000149 · Cited by 81
Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma
Abraha, I., Aristei, C., Palumbo, I., Lupattelli, M., Trastulli, S., Cirocchi, R., Florio, R. D., & Valentini, V. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002102.pub3 · Cited by 78
Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review
Roeder, F., Meldolesi, E., Gerum, S., Valentini, V., & Rödel, C. M. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01695-0 · Cited by 77
Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer
Sanoff, H. K., Moon, D. H., Moore, D. T., Boles, J., Bui, C., Blackstock, W., O'Neil, B. H., Subramaniam, S., McRee, A. J., Carlson, C., et al. (2019) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2019.02.021 · Cited by 72
Elevated CEA Levels and Low Distance of the Tumor from the Anal Verge are Predictors of Incomplete Response to Chemoradiation in Patients with Rectal Cancer
Restivo, A., Zorcolo, L., Cocco, I. M. F., Manunza, R., Margiani, C., Marongiu, L., & Casula, G. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2669-8 · Cited by 75
Telomere-Specific Reverse Transcriptase (hTERT) and Cell-free RNA in Plasma as Predictors of Pathologic Tumor Response in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy
Pucciarelli, S., Rampazzo, E., Briarava, M., Maretto, I., Agostini, M., Digito, M., Keppel, S., Friso, M. L., Lonardi, S., Paoli, A. D., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2272-z · Cited by 70
Self-citation
Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients
Macchia, G., Gambacorta, M. A., Masciocchi, C., Chiloiro, G., Mantello, G., di Benedetto, M., Lupattelli, M., Palazzari, E., Belgioia, L., Bacigalupo, A., et al. (2017) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2017.04.004 · Cited by 69
Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer
Bernier, L., Balyasnikova, S., Tait, D., & Brown, G. M. (2018) · Current Colorectal Cancer Reports · doi:10.1007/s11888-018-0398-5 · Cited by 71
EURECCA consensus conference highlights about rectal cancer clinical management: The radiation oncologist’s expert review
Valentini, V., Glimelius, B. L. G., Haustermans, K. M., Marijnen, C. A. M., Rödel, C. M., Gambacorta, M. A., Boelens, P. G., Aristei, C., & van de Velde, C. J. �. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.10.024 · Cited by 70
Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study
Zhu, J. Y., Liu, F., Gu, W., Lian, P., Sheng, W., Xu, J., Cai, G., Shi, D., Cai, S., & Zhang, Z. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-70 · Cited by 68
Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer
Li, Z., Wang, X., Li, M., Liu, X.-J., Ye, Z., Song, B., Yuan, F., Yuan, Y., Xia, C., Zhang, X., et al. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i19.2388 · Cited by 69
Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: A meta analysis
An, X., Lin, X., Wang, F.-H., Goodman, K. A., Cai, P., Kong, L.-H., Fang, Y., Gao, Y., Lin, J., Wan, D.-S., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.09.026 · Cited by 66
A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer
Hasegawa, S., Goto, S., Matsumoto, T., Hida, K., Kawada, K., Matsusue, R., Yamaguchi, T., Nishitai, R., Manaka, D., Kato, S., et al. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-5967-3 · Cited by 66
Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: Report on late toxicity and outcome
Engels, B., Platteaux, N., den Begin, R. V., Gevaert, T., Sermeus, A. B. L., Storme, G. A., Verellen, D., & Ridder, M. D. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.10.026 · Cited by 65
Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and meta‐analysis
Kong, J. C. H., Guerra, G., Warrier, S. K., Lynch, A. C., Michael, M., Ngan, S. Y., Phillips, W. A., Ramsay, G., & Heriot, A. G. (2018) · Colorectal Disease · doi:10.1111/codi.14106 · Cited by 64
Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer
Restivo, A., Cocco, I. M. F., Casula, G., Scintu, F., Cabras, F., Scartozzi, M., & Zorcolo, L. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.336 · Cited by 63
Early and Late Toxicity of Radiotherapy for Rectal Cancer
Joye, I., & Haustermans, K. M. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-08060-4_13 · Cited by 64
Neoadjuvant Sandwich Treatment With Oxaliplatin and Capecitabine Administered Prior to, Concurrently With, and Following Radiation Therapy in Locally Advanced Rectal Cancer: A Prospective Phase 2 Trial
Gao, Y., Lin, J., An, X., Luo, J.-L., Cai, M.-Y., Cai, P., Kong, L.-H., Liu, G., Tang, J.-H., Chen, G., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.07.021 · Cited by 60
Neoadjuvant Chemoradiation for Distal Rectal Cancer: 5-Year Updated Results of a Randomized Phase 2 Study of Neoadjuvant Combined Modality Chemoradiation for Distal Rectal Cancer
Mohiuddin, M., Paulus, R., Mitchell, E. P., Hanna, N. N., Yuen, A., Nichols, R. C., Yalavarthi, S., Hayostek, C. J., & Willett, C. G. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.02.020 · Cited by 60
Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: The French randomised trial ACCORD12/0405 PRODIGE 2
Rullier, A., Gourgou-Bourgade, S., Jarlier, M., Bibeau, F., Chassagne‐Clément, C., Hennequin, C., Tisseau, L., Leroux, A., Ettore, F., Péoc’h, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.028 · Cited by 58
Review of systemic therapies for locally advanced and metastatic rectal cancer.
Yaffee, P. M., Osipov, A., Tan, C. R. C., Tuli, R., & Hendifar, A. E. (2015) · PubMed Central · doi:10.3978/j.issn.2078-6891.2014.112 · Cited by 60
Thymidylate Synthase Genotype-Directed Neoadjuvant Chemoradiation for Patients With Rectal Adenocarcinoma
Tan, B. R., Thomas, F., Myerson, R. J., Zehnbauer, B. A., Trinkaus, K. M., Malyapa, R. S., Mutch, M. G., Abbey, E. E., Alyasiry, A., Fleshman, J. W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.3212 · Cited by 56

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
Rödel, C. M., Graeven, U., Fietkau, R., Hohenberger, W., Hothorn, T., Arnold, D., Hofheinz, R., Ghadimi, M. B., Wolff, H. A., Lang-Welzenbach, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00159-x · Cited by 736
Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial
Aschele, C., Pinto, C., Cordio, S., Rosati, G., Tagliagambe, A., Artale, S., Rosetti, P., Lonardi, S., Boni, L., & Cionini, L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18s.cra4008 · Cited by 13
Self-citation
Final results of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer.
Aschele, C., Lonardi, S., Cionini, L., Pinto, C., Cordio, S. S., Rosati, G., Bianchi, A. S., Tagliagambe, A., Frisinghelli, M., Zagonel, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3521 · Cited by 42
Self-citation
Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma
Djellali, L., Larbaoui, B., Boukerche, A., Ghazi, S. H., Chaiba, I., Meziane, N., Yekrou, D., & Youcef, D. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.e15108 · Cited by 1
A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer.
Chitapanarux, I., Chitapanarux, T., Tharavichitkul, E., Mayurasakorn, S., Siriwittayakorn, P., Yamada, S., & Lorvidhaya, V. (2011) · PubMed Central · doi:10.2349/biij.7.4.e25 · Cited by 5

See all

Authors: Aschele, C., Cionini, L., Lonardi, S., Pinto, C., Cordio, S., Rosati, G., Artale, S., Tagliagambe, A., Ambrosini, G., Rosetti, P., Bonetti, A., Negru, M. E., Tronconi, M. C., Luppi, G., Silvano, G., Corsi, D. C., Bochicchio, A. M., Chiaulon, G., Gallo, M., & Boni, L.
Affiliations: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
ORCID: Aschele, Carlo
Lonardi, Sara
Pinto, Carmine
Rosati, Gerardo
Bonetti, Andrea
Tronconi, Maria Chiara
Luppi, Gabriele
Silvano, Giovanni
Corsi, Domenico Cristiano
Bochicchio, Anna Maria
Boni, Luca
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2011-07-10
Volume: 29
Issue: 20
Pages: 2773-2780
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2010.34.4911
OpenAlex: W2123712900
Cited by: 763
References: 29
Citations by year: 2026: 8 · 2025: 23 · 2024: 24 · 2023: 21 · 2022: 37 · 2021: 42 · 2020: 60 · 2019: 60 · 2018: 59 · 2017: 72 · 2016: 61 · 2015: 83 · 2014: 62 · 2013: 64 · 2012: 69
FWCI: 33.33
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Amgen
Sanofi
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords: locally advanced rectal cancer, neoadjuvant chemoradiotherapy, oxaliplatin, 5-fluorouracil, pelvic radiotherapy, pathological complete response, circumferential resection margin, lymph node metastasis, treatment toxicity, abdominoperineal resection, overall survival
MeSH terms: Oxaliplatin, Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Fluorouracil, Humans, Italy, Male, Middle Aged, Organoplatinum Compounds, Rectal Neoplasms, Survival Analysis, Dose Fractionation, Radiation, Neoadjuvant Therapy, Medication Adherence, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks